These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 24685455

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oritavancin: mechanism of action.
    Zhanel GG, Schweizer F, Karlowsky JA.
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S214-9. PubMed ID: 22431851
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.
    Chang JD, Foster EE, Thadani AN, Ramirez AJ, Kim SJ.
    J Bacteriol; 2017 Aug 01; 199(15):. PubMed ID: 28507244
    [Abstract] [Full Text] [Related]

  • 7. Conformational and quantitative characterization of oritavancin-peptidoglycan complexes in whole cells of Staphylococcus aureus by in vivo 13C and 15N labeling.
    Cegelski L, Steuber D, Mehta AK, Kulp DW, Axelsen PH, Schaefer J.
    J Mol Biol; 2006 Apr 07; 357(4):1253-62. PubMed ID: 16483598
    [Abstract] [Full Text] [Related]

  • 8. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance.
    Kim SJ, Cegelski L, Preobrazhenskaya M, Schaefer J.
    Biochemistry; 2006 Apr 25; 45(16):5235-50. PubMed ID: 16618112
    [Abstract] [Full Text] [Related]

  • 9. Molecular dynamics simulations of the secondary-binding site in disaccharide-modified glycopeptide antibiotics.
    Olademehin OP, Shuford KL, Kim SJ.
    Sci Rep; 2022 Apr 30; 12(1):7087. PubMed ID: 35490171
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT, Tsuji BT.
    Pharmacotherapy; 2010 Jan 30; 30(1):80-94. PubMed ID: 20030476
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glycopeptide antibiotics and their novel semi-synthetic derivatives.
    Jeya M, Moon HJ, Lee KM, Kim IW, Lee JK.
    Curr Pharm Biotechnol; 2011 Aug 30; 12(8):1194-204. PubMed ID: 21470154
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.